Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with ...

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $10 from $7 and keeps a Buy rating ...

DiaMedica Therapeutics Inc.’s DMAC share price has dipped by 13.02%, which has investors questioning if this is right time to buy.

Astria Therapeutics, Inc.’s ATXS share price has surged by 10.36%, which has investors questioning if this is right time to ...

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are ...

Compared to traditional kallikrein activity assays that use the enzyme in solution with fluorimetric detection, the proposed method offers several advantages. It allows for enzyme reuse, reducing ...

Introduction: The complement and kallikrein-kinin systems (KKS) are both activated during vascular inflammation, and there are many known interactions between the two systems. This study investigated ...

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors ...

Department of Preventive Dentistry, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering ...

By inhibiting plasma kallikrein, ORLADEYO suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients. BioCryst was founded in 1986, and completed its ...

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the ...